| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard University Medical School, Boston, MA 02115;
Boston University Goldman School of Dental Medicine, Boston, MA 02118; and
Cell Signaling Technology, Beverly, MA 01915
Lipoxins and their aspirin-triggered 15-epimers are endogenous anti-inflammatory agents that block neutrophil chemotaxis in vitro and inhibit neutrophil influx in several models of acute inflammation. In this study, we examined the effects of 15-epi-16-(p-fluoro)-phenoxy-lipoxin A4 methyl ester, an aspirin-triggered lipoxin A4-stable analog (ATLa), on the protein phosphorylation pattern of human neutrophils. Neutrophils stimulated with the chemoattractant fMLP were found to exhibit intense phosphorylation of a 55-kDa protein that was blocked by ATLa (10–50 nM). This 55-kDa protein was identified as leukocyte-specific protein 1, a downstream component of the p38-MAPK cascade in neutrophils, by mass spectrometry, Western blotting, and immunoprecipitation experiments. ATLa (50 nM) also reduced phosphorylation/activation of several components of the p38-MAPK pathway in these cells (MAPK kinase 3/MAPK kinase 6, p38-MAPK, MAPK-activated protein kinase-2). These results indicate that ATLa exerts its anti-inflammatory effects, at least in part, by blocking activation of the p38-MAPK cascade in neutrophils, which is known to promote chemotaxis and other proinflammatory responses by these cells.
This article has been cited by other articles:
|
|
 |
|
  A. R. Anand, A. Prasad, R. R. Bradley, Y. S. Deol, T. Nagaraja, X. Ren, E. F. Terwilliger, and R. K. Ganju HIV-1 gp120-induced migration of dendritic cells is regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1 Blood, October 22, 2009; 114(17): 3588 - 3600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kronke, J. Katzenbeisser, S. Uderhardt, M. M. Zaiss, C. Scholtysek, G. Schabbauer, A. Zarbock, M. I. Koenders, R. Axmann, J. Zwerina, et al. 12/15-Lipoxygenase Counteracts Inflammation and Tissue Damage in Arthritis J. Immunol., September 1, 2009; 183(5): 3383 - 3389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Starosta, K. Pazdrak, I. Boldogh, T. Svider, and A. Kurosky Lipoxin A4 Counterregulates GM-CSF Signaling in Eosinophilic Granulocytes J. Immunol., December 15, 2008; 181(12): 8688 - 8699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Omori, T. Ohira, Y. Uchida, S. Ayilavarapu, E. L. Batista Jr., M. Yagi, T. Iwata, H. Liu, H. Hasturk, A. Kantarci, et al. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase J. Leukoc. Biol., July 1, 2008; 84(1): 292 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Haworth and B. D. Levy Endogenous lipid mediators in the resolution of airway inflammation Eur. Respir. J., November 1, 2007; 30(5): 980 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Chiang, C. N. Serhan, S.-E. Dahlen, J. M. Drazen, D. W. P. Hay, G. E. Rovati, T. Shimizu, T. Yokomizo, and C. Brink The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo Pharmacol. Rev., September 1, 2006; 58(3): 463 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. G. Hayhoe, A. M. Kamal, E. Solito, R. J. Flower, D. Cooper, and M. Perretti Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement Blood, March 1, 2006; 107(5): 2123 - 2130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Reville, J. K. Crean, S. Vivers, I. Dransfield, and C. Godson Lipoxin A4 Redistributes Myosin IIA and Cdc42 in Macrophages: Implications for Phagocytosis of Apoptotic Leukocytes J. Immunol., February 1, 2006; 176(3): 1878 - 1888. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
